Sentien Biotechnologies, Inc. (sentienbiotech.com) is a privately owned, clinical stage company developing novel approaches to cell therapy. Its lead product combines mesenchymal stromal cells (MSCs) within an approved blood-filtration device, allowing for controlled, sustained delivery of MSC secreted factors. This product is being tested to treat systemic inflammatory diseases where MSCs can condition blood continuously during an acute illness.
Sentien has received numerous SBIR awards from the U.S. National Institutes of Health and obtained a seed round of financing in August of 2015.
In the fall of 2016, Boehringer Ingelheim named Sentien its first LabCentral Golden Ticket winner. The Golden Ticket program enables high-level sponsors to underwrite the cost of a lab bench for a scientist to reside in the innovative, shared laboratory space for one year.